OBJECTIVES: To evaluate quality of life (QoL) and related variables in patients with ankylosing spondylitis (AS), a chronic inflammatory disease of the spine. METHODS: Nine-hundred and sixty-two patients with AS from the Turkish League Against Rheumatism AS Registry, who fulfilled the modified New York criteria, were enrolled. The patients were evaluated using the Assessment of SpondyloArthritis International Society core outcome domains including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), fatigue (BASDAI-question 1), pain (last week/spine/due to AS), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Radiology Index (BASRI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and two QoL questionnaires (the disease-specific ASQoL and generic the Short Form-36 [SF-36]). RESULTS: The mean ASQoL score was 7.1 ± 5.7. SF-36 subscales of general health, physical role and bodily pain had the poorest scores. ASQoL was strongly correlated with disease duration, BASDAI, fatigue, BASFI, BASMI, BASRI, MASES, pain and SF-36 subscales (P < 0.001). SF-36 subscales were also strongly correlated with BASDAI and BASFI. Advanced educational status and regular exercise habits positively affected QoL, while smoking negatively affected QoL. CONCLUSIONS: In patients with AS, the most significant variables associated with QoL were BASDAI, BASFI, fatigue and pain. ASQoL was noted to be a short, rapid and simple patient-reported outcome (PRO) instrument and strongly correlated with SF-36 subscales.
OBJECTIVES: To evaluate quality of life (QoL) and related variables in patients with ankylosing spondylitis (AS), a chronic inflammatory disease of the spine. METHODS: Nine-hundred and sixty-two patients with AS from the Turkish League Against Rheumatism AS Registry, who fulfilled the modified New York criteria, were enrolled. The patients were evaluated using the Assessment of SpondyloArthritis International Society core outcome domains including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), fatigue (BASDAI-question 1), pain (last week/spine/due to AS), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Radiology Index (BASRI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and two QoL questionnaires (the disease-specific ASQoL and generic the Short Form-36 [SF-36]). RESULTS: The mean ASQoL score was 7.1 ± 5.7. SF-36 subscales of general health, physical role and bodily pain had the poorest scores. ASQoL was strongly correlated with disease duration, BASDAI, fatigue, BASFI, BASMI, BASRI, MASES, pain and SF-36 subscales (P < 0.001). SF-36 subscales were also strongly correlated with BASDAI and BASFI. Advanced educational status and regular exercise habits positively affected QoL, while smoking negatively affected QoL. CONCLUSIONS: In patients with AS, the most significant variables associated with QoL were BASDAI, BASFI, fatigue and pain. ASQoL was noted to be a short, rapid and simple patient-reported outcome (PRO) instrument and strongly correlated with SF-36 subscales.
Authors: L C Doward; A Spoorenberg; S A Cook; D Whalley; P S Helliwell; L J Kay; S P McKenna; A Tennant; D van der Heijde; M A Chamberlain Journal: Ann Rheum Dis Date: 2003-01 Impact factor: 19.103
Authors: Ahmet Ozgül; Fatma Peker; M Ali Taskaynatan; A Kenan Tan; Kemal Dinçer; Tunç Alp Kalyon Journal: Clin Rheumatol Date: 2005-08-10 Impact factor: 2.980
Authors: H Bodur; S Ataman; L Akbulut; D Evcik; V Kavuncu; T Kaya; R Günaydin; B Kuran; N Kotevoğlu; A Bal; E Aydoğ; Z Altay; H Uğurlu; H Kocabaş; N Olmez; P Yazgan; S Gürsoy; E Madenci; S Ozel; S U Delialioğlu Journal: Clin Rheumatol Date: 2008-03-21 Impact factor: 2.980
Authors: L Heuft-Dorenbosch; A Spoorenberg; A van Tubergen; R Landewé; H van ver Tempel; H Mielants; M Dougados; D van der Heijde Journal: Ann Rheum Dis Date: 2003-02 Impact factor: 19.103
Authors: Sofia Manuela da Rocha Lopes; José Alberto Duarte; Cristina Teresa Torrão Carvalho Mesquita Journal: Rheumatol Int Date: 2016-02-08 Impact factor: 2.631
Authors: M T Duruöz; L Doward; Y Turan; L Cerrahoglu; M Yurtkuran; M Calis; N Tas; S Ozgocmen; O Yoleri; B Durmaz; S Oncel; T Tuncer; O Sendur; M Birtane; F Tuzun; U Bingol; M Kirnap; G Celik Erturk; O Ardicoglu; A Memis; F Atamaz; R Kizil; C Kacar; G Gurer; K Uzunca; H Sari Journal: Rheumatol Int Date: 2013-06-14 Impact factor: 2.631